Komori
Other Disclosures2158FRONTEO,Inc.Information and Communications, Services and Others

JT’s corporate R&D organization “D-LAB” adopts FRONTEO’s “KIBIT Amanogawa” AI for searching medical literature

Use of FRONTEO’s medical literature search AI “KIBIT Amanogawa” has begun at JAPAN TOBACCO INC.’s corporate R&D organization “D-LAB.” D-LAB will use the AI in research to identify new technology seeds and business hypotheses, not limited to drug discovery.

Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
40000000
Medical and life sciences papers
Wording
Conditional
How definitive the wording is.

Announced details

KIBIT Amanogawa (AI system for searching medical literature)
Applicable field (uses covered by this announcement)
Searches for medical and life sciences papersDrug Discovery ResearchExploration of technology and business seedsResearch in science and technologyResearch into experience designCosmeticsHealthcareFoodMaterial
Launch date8 October 2026 (use commenced, actual)
What the company reported numerically
Usage history

Use at D-LAB has begun (number of uses and number of adopting companies: Not disclosed)

Relationship between the counterparty and the company
FRONTEO,Inc.2158
Relationship with the Company

FRONTEO introduced KIBIT Amanogawa to JAPAN TOBACCO INC.’s corporate R&D organization “D-LAB.” Other capital or personnel ties: Not disclosed.

CounterpartyJAPAN TOBACCO INC.

Head office: Minato-ku, Tokyo; President and Representative Director: Tsutsui Takehiko (筒井 岳彦). The company has a corporate R&D organization, “D-LAB,” which conducts activities including the exploration and creation of science and technology, experience design and business seeds without being constrained by existing business areas.

Location (as indicated in this announcement)

D-LAB is advancing more than 100 projects on an ongoing basis

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredKIBIT Amanogawa (AI system for searching medical literature)
CounterpartyJAPAN TOBACCO INC.
Counterparty overviewHead office: Minato-ku, Tokyo; President and Representative Director: Tsutsui Takehiko (筒井 岳彦). The company has a corporate R&D organization, “D-LAB,” which conducts activities including the exploration and creation of science and technology, experience design and business seeds without being constrained by existing business areas.
Relationship with the CompanyFRONTEO introduced KIBIT Amanogawa to JAPAN TOBACCO INC.’s corporate R&D organization “D-LAB.” Other capital or personnel ties: Not disclosed.
Launch date8 October 2026 (use commenced, actual)
Applicable areaSearches for medical and life sciences papers, Drug Discovery Research, Exploration of technology and business seeds, Research in science and technology, Research into experience design, Cosmetics, Healthcare, Food, Material
Location scaleD-LAB is advancing more than 100 projects on an ongoing basis
Usage historyUse at D-LAB has begun (number of uses and number of adopting companies: Not disclosed)
Items this document does not state (10)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationQuantitative EffectsImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

As part of D-LAB’s research and exploration activities, to help generate hypotheses, ideas and new value that are difficult to find using existing knowledge alone.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
JT’s corporate R&D organization “D-LAB” adopts FRONTEO’s “KIBIT Amanogawa” AI for searching medical literature | FRONTEO,Inc. (2158) timely disclosure | Komori